Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Wynn

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Clinical Genetics|April 28, 2018
Refining the phenotype associated with biallelic DNAJC21 mutationsG D'Amours, F Lopes, J Gauthier, et al.
Annals of Neurology|April 25, 2006
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosisHillel S Panitch, Ronald A Thisted, Richard A Smith, et al.
Protein Expression and Purification|October 26, 2001
A comprehensive system for protein purification and biochemical analysis based on antibodies to c-myc peptideM C Hillman, L S Yang, S Sun, et al.
Journal of the Neurological Sciences|March 19, 2010
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosisErnst-Wilhelm Radue, William H Stuart, Peter A Calabresi, et al.
The Lancet. Neurology|March 15, 2011
Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomesAlasdair J Coles, Edward Fox, Anton Vladic, et al.
Pharmacogenomics|May 28, 2010
From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice systemSteven H Y Wong, Christopher Happy, Dan Blinka, et al.
Journal of Neurology|March 25, 2009
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINELMichael Hutchinson, Ludwig Kappos, Peter A Calabresi, et al.
Neurology|September 1, 2007
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELP A Calabresi, G Giovannoni, C Confavreux, et al.
Annals of Neurology|August 19, 2007
Health-related quality of life in multiple sclerosis: effects of natalizumabRichard A Rudick, Deborah Miller, Steve Hass, et al.
Neurology|April 18, 2007
Natalizumab reduces visual loss in patients with relapsing multiple sclerosisL J Balcer, S L Galetta, P A Calabresi, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Clinical Genetics|April 28, 2018
Refining the phenotype associated with biallelic DNAJC21 mutationsG D'Amours, F Lopes, J Gauthier, et al.
Annals of Neurology|April 25, 2006
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosisHillel S Panitch, Ronald A Thisted, Richard A Smith, et al.
Protein Expression and Purification|October 26, 2001
A comprehensive system for protein purification and biochemical analysis based on antibodies to c-myc peptideM C Hillman, L S Yang, S Sun, et al.
Journal of the Neurological Sciences|March 19, 2010
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosisErnst-Wilhelm Radue, William H Stuart, Peter A Calabresi, et al.
The Lancet. Neurology|March 15, 2011
Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomesAlasdair J Coles, Edward Fox, Anton Vladic, et al.
Pharmacogenomics|May 28, 2010
From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice systemSteven H Y Wong, Christopher Happy, Dan Blinka, et al.
Journal of Neurology|March 25, 2009
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINELMichael Hutchinson, Ludwig Kappos, Peter A Calabresi, et al.
Neurology|September 1, 2007
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELP A Calabresi, G Giovannoni, C Confavreux, et al.
Annals of Neurology|August 19, 2007
Health-related quality of life in multiple sclerosis: effects of natalizumabRichard A Rudick, Deborah Miller, Steve Hass, et al.
Neurology|April 18, 2007
Natalizumab reduces visual loss in patients with relapsing multiple sclerosisL J Balcer, S L Galetta, P A Calabresi, et al.
Pageof 12